🔥🐔 BizChicken 🐔🔥

Companies Similar to Celcuity Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CY6463

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.

Tags: CNS diseases, CY6463, biopharmaceutical, clinical-stage, therapy development

Symbol: CYCN

Recent Price: $3.45

Industry: Biotechnology

CEO: Dr. Regina Graul Ph.D.

Sector: Healthcare

Employees: 1

Address: 245 First Street, Cambridge, MA 02142

Phone: 857 327 8778

Last updated: 2024-12-31

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

Precigen, Inc.

Precigen, Inc. logo
Market Cap: Low
Employees: Low

gene and cellular therapies

Precigen, Inc. is focused on discovering and developing advanced gene and cellular therapies, disease-modifying therapeutics, and genetic engineering technologies for regenerative medicine and other applications.

Tags: biotechnology, cellular therapy, gene therapy, genetic engineering, regenerative medicine

Symbol: PGEN

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Helen Sabzevari MPH, Ph.D.

Sector: Healthcare

Employees: 202

Address: 20374 Seneca Meadows Parkway, Germantown, MD 20876

Phone: 301 556 9900

Last updated: 2024-12-31

PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. logo
Market Cap: Lowest
Employees: Lowest

Cell-in-a-Box

Pharma Cyte Biotech, Inc. is a biotechnology company focused on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. Their therapies are based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology, used for treating various cancers and diabetes.

Tags: Cell-in-a-Box, biotechnology, cancer, cannabis plant, cellular therapies, diabetes, insulin-dependent diabetes, live cell encapsulation, pancreatic cancer

Symbol: PMCB

Recent Price: $1.55

Industry: Biotechnology

CEO: Mr. Joshua N. Silverman

Sector: Healthcare

Employees: 2

Address: 3960 Howard Hughes Parkway, Las Vegas, NV 89169

Phone: 917 595 2850

Leadership

  • Joshua N. Silverman, Independent Director
  • Dr. Michael M. Abecassis, Independent Director
  • Robert Weinstein, Director
  • Wayne R. Walker, Director
  • Jonathan L. Schechter, Independent Director
  • Dr. Abecassis, Director
  • Kenneth L. Waggoner, Independent Director
  • Daniel C. Farb, Independent Director
  • Daniel C. Allen, Independent Director
  • Jack E. Stover, Independent Director

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Celcuity Inc.

Celcuity Inc. logo
Market Cap: Medium
Employees: Lowest

CELsignia diagnostic platform

Celcuity Inc., a biotechnology company, develops targeted therapies for cancer patients in the US, including the CELsignia diagnostic platform and Gedatolisib drug candidate.

Tags: Gedatolisib, HER2-negative, biotechnology, breast cancer, cancer therapy, diagnostic platform

Symbol: CELC

Recent Price: $13.13

Industry: Biotechnology

CEO: Mr. Brian F. Sullivan

Sector: Healthcare

Employees: 55

Address: 16305–36th Avenue North, Minneapolis, MN 55446

Phone: 763 392 0767

Leadership

  • Brian Sullivan, CEO and Co-founder
  • Lance Laing, PhD, Chief Science Officer and Co-founder
  • Vicky Hahne, CFO
  • Igor Gorbatchevsky, MD, Chief Medical Officer
  • Eldon Mayer, Chief Commercial Officer
  • Brent Eilefson, General Counsel
  • Bernhard Lampert, PhD, VP of Pharmaceutical Development
  • Nadene Zack, VP Clinical Operations
  • Sunni Miller, VP of Regulatory Affairs
  • David Bridge, VP of Quality Assurance and Process Development
  • William Strickland, PharmD, VP of Medical Affairs
  • Fred Kerwood, VP of Program Management
  • Charlotte Moser, MD, PhD, SVP of Clinical Development
  • John R. MacDonald, PhD, SVP of R&D
  • Lance Laing, PhD, Chief Science Officer and Co-Founder
  • Richard Buller, MD, PhD, Director
  • David F. Dalvey, Director
  • Leo Furcht, MD, Director
  • Polly Murphy, DVM, PhD, Director
  • Richard J. Nigon, Director

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. logo
Market Cap: High
Employees: Low

therapeutic monoclonal and bispecific antibodies

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.

Tags: biopharmaceutical, bispecific antibodies, cancer treatment, inflammatory diseases, monoclonal antibodies

Symbol: CLDX

Recent Price: $25.12

Industry: Biotechnology

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Employees: 160

Address: Perryville III Building, Hampton, NJ 08827

Phone: 908 200 7500

Leadership

  • Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
  • Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
  • Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Sam Martin, Senior Vice President and Chief Financial Officer
  • Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
  • Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
  • Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
  • Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
  • Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
  • Keith L. Brownlie, Former Partner, Ernst & Young LLP
  • Herbert J. Conrad, Former President, Roche Pharmaceuticals US
  • James J. Marino, J.D., Former Partner, Dechert LLP
  • Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
  • Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
  • Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
  • Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
  • Carl June, M.D.,
  • Michel Nussenzweig, M.D., Ph.D.,
  • Marc E. Rothenberg M.D., Ph.D.,
  • Joseph Schlessinger, Ph.D.,
  • Louis Weiner, M.D.,

Last updated: 2024-12-31

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

CLR 131

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.

Tags: biopharmaceutical, cancer treatment, drug development, phospholipid drug conjugate

Symbol: CLRB

Recent Price: $0.29

Industry: Biotechnology

CEO: Mr. James V. Caruso

Sector: Healthcare

Employees: 20

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 608 441 8120

Leadership

  • James Caruso, President, CEO and Director
  • Chad Kolean, Chief Financial Officer
  • Shane Lea, Chief Commercial Officer
  • Jarrod Longcor, Chief Operating Officer
  • Andrei Shustov, Senior Vice President, Medical
  • Douglas J. Swirsky, Chairman of the Board
  • Asher Alban Chanan-Khan, MD., Director
  • Frederick W. Driscoll, Director
  • Stefan D. Loren, Ph.D., Director
  • John Neis, Director
  • Cellectar Biosciences, Inc., Company Information

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Century Therapeutics, Inc.

Century Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

CNTY-101

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Tags: CAR-i NK, CAR-i T, allogeneic, biotechnology, cell therapy, hematological malignancies, iPSC, solid tumors

Symbol: IPSC

Recent Price: $1.00

Industry: Biotechnology

CEO: Mr. Brent Pfeiffenberger M.B.A., Pharm.D.

Sector: Healthcare

Employees: 152

Address: 3675 Market Street, Philadelphia, PA 19104

Phone: 267 817 5790

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Solid Biosciences Inc.

Solid Biosciences Inc. logo
Market Cap: Low
Employees: Low

SGT-001

Solid Biosciences Inc. focuses on developing therapies for Duchenne muscular dystrophy, with lead product candidates like SGT-001 and SGT-003, and platform technologies like dual gene expression. The company is headquartered in Cambridge, Massachusetts, and collaborates with Ultragenyx Pharmaceutical Inc.

Tags: Duchenne muscular dystrophy, SGT-001, biotechnology, clinical trials, gene therapy

Symbol: SLDB

Recent Price: $4.07

Industry: Biotechnology

CEO: Mr. Alexander G. Cumbo

Sector: Healthcare

Employees: 88

Address: 141 Portland Street, Cambridge, MA 02139

Phone: 617 337 4680

Leadership

  • Ian F. Smith, Chairman of the Board
  • Bo Cumbo, President and CEO
  • Martin Freed, M.D., F.A.C.P., Board Member
  • Ilan Ganot, Co-Founder and Strategic Advisor to the CEO
  • Clare Kahn, Ph.D., Board Member
  • Georgia Keresty, Ph.D., M.PH., Board Member
  • Sukumar Nagendran, M.D., President, Head of Research & Development, Taysha Gene Therapies
  • Adam Stone, Chief Investment Officer of Perceptive Advisors
  • Lynne Sullivan, Chief Financial Officer at Unity Biotechnology

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Veracyte, Inc.

Veracyte, Inc. logo
Market Cap: High
Employees: Medium

Afirma Genomic Sequencing Classifier, Xpression Atlas, Decipher Prostate, Prosigna Breast Cancer Assay, Percepta Genomic Sequencing Classifier, Envisia Genomic Classifier, Immunoscore Colon Cancer test

Veracyte, Inc. operates as a diagnostics company worldwide, providing genomic testing solutions for various cancers and diseases, aiming to improve outcomes by avoiding unnecessary surgeries and enhancing treatment decisions.

Tags: Biotechnology, Cancer Diagnosis, Diagnostics, Genomic Testing, Healthcare, Medical Devices

Symbol: VCYT

Recent Price: $40.00

Industry: Biotechnology

CEO: Mr. Marc A. Stapley

Sector: Healthcare

Employees: 815

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 650 243 6300

Last updated: 2024-12-31

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Imm Celz

Creative Medical Technology Holdings, Inc. is a biotechnology company focusing on using adult stem cell treatments for immunology, urology, orthopedics, and neurology, offering solutions like Caver Stem, Fem Celz, Stem Spine, Imm Celz, and Ova Stem.

Tags: biotechnology, immunology, neurology, orthopedics, stem cell treatments, urology

Symbol: CELZ

Recent Price: $2.34

Industry: Biotechnology

CEO: Mr. Timothy Warbington

Sector: Healthcare

Employees: 4

Address: 211 East Osborn Road, Phoenix, AZ 85012

Phone: 480 399 2822

Last updated: 2024-12-31

Cullinan Oncology, Inc.

Cullinan Oncology, Inc. logo
Market Cap: Medium
Employees: Low

CLN-081

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.

Tags: biopharmaceutical, cancer, clinical trials, immuno-oncology, oncology, therapies

Symbol: CGEM

Recent Price: $12.20

Industry: Biotechnology

CEO: Mr. Nadim Ahmed

Sector: Healthcare

Employees: 85

Address: One Main Street, Cambridge, MA 02142

Phone: 617 410 4650

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Medium

RNA-targeted therapeutics

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.

Tags: ALS, Biotechnology, Pharmaceuticals, RNA therapeutics, SPINRAZA, TEGSEDI, TTR amyloidosis, WAYLIVRA

Symbol: IONS

Recent Price: $34.92

Industry: Biotechnology

CEO: Dr. Brett P. Monia Ph.D.

Sector: Healthcare

Employees: 927

Address: 2855 Gazelle Court, Carlsbad, CA 92010

Phone: 760 931 9200

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31